Multivalent DNA-Based Immunization against Hepatitis B Virus with Plasmids Encoding Surface and Core Antigens

Connie, "Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters" (2008 b s t r a c tTo determine if DNA vaccines for two hantaviruses causing hemorrhagic fever with renal syndrome, Hantaan virus and Puumala virus, are immunogenic when given in combination, we delivered them to hamsters separately or as mixtures by gene gun or by electroporation. Both vaccines elicited neutralizing antibodies when given alone but when they were delivered as a mixture, antibodies to only one of the two hantaviruses could be detected. In contrast, if the DNAs were given as separate vaccinations to a single animal, responses to both were observed. These studies suggest that the two DNA vaccines will need to be given as separate administrations.Published by Elsevier Ltd.

Section: Discussioncontrasting

confidence: 82%

Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters

Spik

Badger

Mathiessen³

et al. 2008

“…In addition, T-cell responses were generally lower when the mixture was given [41]. Other studies, however, have not shown interference when similar genes are delivered (e.g., multiple HIV-1 genes from different clades [42]); or when two genes from the same virus are given (e.g., hepatitis B surface and core genes [43]). …”

Section: Discussionmentioning

confidence: 96%

Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus

Spik

Shurtleff

McElroy

et al. 2006

132

109

DNA vaccines for Rift Valley fever virus (RVFV), Crimean Congo hemorrhagic fever virus (CCHFV), tick-borne encephalitis virus (TBEV), and Hantaan virus (HTNV), were tested in mice alone or in various combinations. The bunyavirus vaccines (RVFV, CCHFV, and HTNV) expressed Gn and Gc genes, and the flavivirus vaccine (TBEV) expressed the preM and E genes. All vaccines were delivered by gene gun. The TBEV DNA vaccine and the RVFV DNA vaccine elicited similar levels of antibodies and protected mice from challenge when delivered alone or in combination with other DNAs. Although in general, the HTNV and CCHFV DNA vaccines were not very immunogenic in mice, there were no major differences in performance when given alone or in combination with the other vaccines. Published by Elsevier Ltd.

“…Although DNA vaccine technology still has many technical hurdles to overcome before it will be used routinely for preventing human diseases, results in clinical studies demonstrate that it is a viable approach [1,2]. To date, few studies of combination DNA vaccines have been reported, with most focusing on multiple genes of a single agent, for example those of the malaria parasite [3], Mycobacterium tuberculosis [4], or hepatitis B virus [5]. No studies have yet been reported on combination vaccines for multiple disparate high-hazard pathogens.…”

Section: Introductionmentioning

confidence: 99%

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus

Riemenschneider

Garrison

Geisbert

et al. 2003

123

Multiagent DNA vaccines for highly pathogenic organisms offer an attractive approach for preventing naturally occurring or deliberately introduced diseases. Few animal studies have compared the feasibility of combining unrelated gene vaccines. Here, we demonstrate that DNA vaccines to four dissimilar pathogens that are known biowarfare agents, Bacillus anthracis, Ebola (EBOV), Marburg (MARV), and Venezuelan equine encephalitis virus (VEEV), can elicit protective immunity in relevant animal models. In addition, a combination of all four vaccines is shown to be equally as effective as the individual vaccines for eliciting immune responses in a single animal species. These results demonstrate for the first time the potential of combined DNA vaccines for these agents and point to a possible method of rapid development of multiagent vaccines for disparate pathogens such as those that might be encountered in a biological attack.